498 related articles for article (PubMed ID: 33432367)
21. Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Park R; Li J; Slebos RJC; Chaudhary R; Poole MI; Ferraris C; Farinhas J; Hernandez-Prera J; Kirtane K; Teer JK; Song X; Hall MS; Tasoulas J; Amelio AL; Chung CH
Oral Oncol; 2024 Jul; 154():106866. PubMed ID: 38820888
[TBL] [Abstract][Full Text] [Related]
22. The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication.
Dou S; Li R; He N; Zhang M; Jiang W; Ye L; Yang Y; Zhao G; Yang Y; Li J; Chen D; Zhu G
Front Immunol; 2021; 12():618367. PubMed ID: 34552580
[TBL] [Abstract][Full Text] [Related]
23. The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma.
Gurin D; Slavik M; Hermanova M; Selingerova I; Kazda T; Hendrych M; Shatokhina T; Vesela M
J Oral Pathol Med; 2020 Oct; 49(9):886-896. PubMed ID: 32516834
[TBL] [Abstract][Full Text] [Related]
24. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F
Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183
[TBL] [Abstract][Full Text] [Related]
25. Transcriptomic and Immunophenotypic Characterization of Tumor Immune Microenvironment in Squamous Cell Carcinoma of the Oral Tongue.
Chatzopoulos K; Sotiriou S; Collins AR; Kartsidis P; Schmitt AC; Chen X; Khazaie K; Hinni ML; Ramsower CA; Zarka MA; Patel SH; Garcia JJ
Head Neck Pathol; 2021 Jun; 15(2):509-522. PubMed ID: 33010009
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma.
Zhang XM; Song LJ; Shen J; Yue H; Han YQ; Yang CL; Liu SY; Deng JW; Jiang Y; Fu GH; Shen WW
Hum Pathol; 2018 Dec; 82():104-112. PubMed ID: 30036594
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of
Togo M; Yokobori T; Shimizu K; Handa T; Kaira K; Sano T; Tsukagoshi M; Higuchi T; Yokoo S; Shirabe K; Oyama T
Br J Cancer; 2020 May; 122(11):1686-1694. PubMed ID: 32238919
[TBL] [Abstract][Full Text] [Related]
28. Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
de la Iglesia JV; Slebos RJC; Martin-Gomez L; Wang X; Teer JK; Tan AC; Gerke TA; Aden-Buie G; van Veen T; Masannat J; Chaudhary R; Song F; Fournier M; Siegel EM; Schabath MB; Wadsworth JT; Caudell J; Harrison L; Wenig BM; Conejo-Garcia J; Hernandez-Prera JC; Chung CH
Clin Cancer Res; 2020 Mar; 26(6):1474-1485. PubMed ID: 31848186
[TBL] [Abstract][Full Text] [Related]
29. Immune cell infiltration in head and neck squamous cell carcinoma and patient outcome: a retrospective study.
Schneider K; Marbaix E; Bouzin C; Hamoir M; Mahy P; Bol V; Grégoire V
Acta Oncol; 2018 Sep; 57(9):1165-1172. PubMed ID: 29493423
[TBL] [Abstract][Full Text] [Related]
30. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
31. CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma.
Nordfors C; Grün N; Tertipis N; Ährlund-Richter A; Haeggblom L; Sivars L; Du J; Nyberg T; Marklund L; Munck-Wikland E; Näsman A; Ramqvist T; Dalianis T
Eur J Cancer; 2013 Jul; 49(11):2522-30. PubMed ID: 23571147
[TBL] [Abstract][Full Text] [Related]
32. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG).
Balermpas P; Rödel F; Rödel C; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Gkika E; Stuschke M; Avlar M; Grosu AL; Abdollahi A; Debus J; Bayer C; Stangl S; Belka C; Pigorsch S; Multhoff G; Combs SE; Mönnich D; Zips D; Fokas E
Int J Cancer; 2016 Jan; 138(1):171-81. PubMed ID: 26178914
[TBL] [Abstract][Full Text] [Related]
33. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
34. A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab.
Kuba K; Inoue H; Matsumura S; Enoki Y; Kogashiwa Y; Ebihara Y; Nakahira M; Yamazaki T; Yasuda M; Kaira K; Kagamu H; Sugasawa M
Sci Rep; 2022 Dec; 12(1):22557. PubMed ID: 36581686
[TBL] [Abstract][Full Text] [Related]
35. Metavariables Resuming Host Immune Features and Nodal Involvement Are Associated with Oncological Outcomes in Oral Cavity Squamous Cell Carcinoma.
Missale F; Bugatti M; Mattavelli D; Lonardi S; Lombardi D; Nicolai P; Piazza C; Battocchio S; Bozzola AM; Calza S; Vermi W
Cells; 2021 Aug; 10(9):. PubMed ID: 34571850
[TBL] [Abstract][Full Text] [Related]
36. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
[TBL] [Abstract][Full Text] [Related]
37. Immune gene expression in head and neck squamous cell carcinoma patients.
Lecerf C; Kamal M; Vacher S; Chemlali W; Schnitzler A; Morel C; Dubot C; Jeannot E; Meseure D; Klijanienko J; Mariani O; Borcoman E; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Choussy O; Hoffmann C; Piaggio E; Bieche I; Le Tourneau C
Eur J Cancer; 2019 Nov; 121():210-223. PubMed ID: 31593831
[TBL] [Abstract][Full Text] [Related]
38. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
[TBL] [Abstract][Full Text] [Related]
39. The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
Chen TC; Wu CT; Wang CP; Lou PJ; Ko JY; Chang YL
Oral Oncol; 2020 Dec; 111():104945. PubMed ID: 32769036
[TBL] [Abstract][Full Text] [Related]
40. Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma.
Brcic I; Gallob M; Schwantzer G; Zrnc T; Weiland T; Thurnher D; Wolf A; Brcic L
Oral Oncol; 2020 Jul; 106():104719. PubMed ID: 32335324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
